|Bid||0.00 x 1200|
|Ask||0.00 x 1000|
|Day's Range||5.90 - 6.65|
|52 Week Range||1.58 - 19.10|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Dec 10, 2020 - Dec 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.00|
TORONTO, ON / ACCESSWIRE / October 19, 2020 / Edesa Biotech, Inc.
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Clinical Trial of EB05 Set to Initiate In April 2020, Edesa (NASDAQ:EDSA) announced an exclusive licensing agreement with Light Chain Bioscience for two clinical-stage monoclonal antibody assets targeting toll-like receptor 4 (TLR4) and C-X-C motif chemokine 10 (CXCL10). Light Chain received Series A-1 Convertible